These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10790596)

  • 1. [The pharmacology of endothelin and its antagonist bosentan].
    Clozel M; Roux S
    Ann Endocrinol (Paris); 2000 Feb; 61(1):75-9. PubMed ID: 10790596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan: a dual endothelin receptor antagonist.
    Rubin LJ; Roux S
    Expert Opin Investig Drugs; 2002 Jul; 11(7):991-1002. PubMed ID: 12084009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin antagonism with bosentan: current status and future perspectives.
    Ono K; Matsumori A
    Cardiovasc Drug Rev; 2002; 20(1):1-18. PubMed ID: 12070530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan and the endothelin system in congestive heart failure.
    Ellahham SH; Charlon V; Abassi Z; Calis KA; Choucair WK
    Clin Cardiol; 2000 Nov; 23(11):803-7. PubMed ID: 11097125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Remarkable response of bosentan, an endothelin receptor antagonist, for a patient with Eisenmenger syndrome].
    Emoto N; Matsuo N; Ohnishi T; Miyagawa K; Kato H; Iwasa N; Yoshida A; Kawai H; Hirata K; Kuroda Y
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2549-51. PubMed ID: 19051748
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
    Musch A
    Med Monatsschr Pharm; 2006 Jul; 29(7):242-5. PubMed ID: 16866076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan).
    Teerlink JR; Löffler BM; Hess P; Maire JP; Clozel M; Clozel JP
    Circulation; 1994 Nov; 90(5):2510-8. PubMed ID: 7955209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin antagonism with bosentan: a review of potential applications.
    Roux S; Breu V; Ertel SI; Clozel M
    J Mol Med (Berl); 1999 Apr; 77(4):364-76. PubMed ID: 10353441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin and heart failure.
    Nambi P; Clozel M; Feuerstein G
    Heart Fail Rev; 2001 Dec; 6(4):335-40. PubMed ID: 11447308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endothelin].
    Maeda S; Miyauchi T; Goto K
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():112-6. PubMed ID: 16895176
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of bosentan for treatment of pulmonary hypertension.
    Raja SG; Dreyfus GD
    Ann Card Anaesth; 2008; 11(1):6-14. PubMed ID: 18182753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension.
    Rondelet B; Kerbaul F; Motte S; van Beneden R; Remmelink M; Brimioulle S; McEntee K; Wauthy P; Salmon I; Ketelslegers JM; Naeije R
    Circulation; 2003 Mar; 107(9):1329-35. PubMed ID: 12628956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin antagonists and heart failure.
    Hürlimann D; Enseleit F; Noll G; Lüscher TF; Ruschitzka F
    Curr Hypertens Rep; 2002 Feb; 4(1):85-92. PubMed ID: 11790297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
    Kaoukis A; Deftereos S; Raisakis K; Giannopoulos G; Bouras G; Panagopoulou V; Papoutsidakis N; Cleman MW; Stefanadis C
    Curr Top Med Chem; 2013; 13(2):95-114. PubMed ID: 23470073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan.
    Clozel M; Salloukh H
    Ann Med; 2005; 37(1):2-12. PubMed ID: 15902842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.
    Kiowski W; Sütsch G; Hunziker P; Müller P; Kim J; Oechslin E; Schmitt R; Jones R; Bertel O
    Lancet; 1995 Sep; 346(8977):732-6. PubMed ID: 7658874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure.
    Webb DJ
    Circulation; 1995 Dec; 92(12):3372. PubMed ID: 8521551
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?
    Kuntzen C; Gülberg V; Gerbes AL
    Gastroenterology; 2005 Jan; 128(1):164-8. PubMed ID: 15633133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
    Kim NH; Rubin LJ
    J Cardiovasc Pharmacol Ther; 2002 Jan; 7(1):9-19. PubMed ID: 12000973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans.
    Sütsch G; Bertel O; Kiowski W
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):717-25. PubMed ID: 9110115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.